 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...115116117118119120121122123124125...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Enrollment change, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Feb 8, 2017
P1, N=16, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=24 --> 16
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (clinicaltrials.gov) - Feb 7, 2017
P2, N=27, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Recruiting --> Active, not recruiting | N=24 --> 16 Trial primary completion date: Oct 2016 --> Dec 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Feb 2, 2017
P1, N=22, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Oct 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA (clinicaltrials.gov) - Feb 1, 2017
P1, N=15, Completed, Sponsor: Northwell Health
Trial primary completion date: Dec 2016 --> Dec 2017 N=30 --> 15
- | Imprime PGG (odetiglucan) / HiberCell
Trial termination, Trial primary completion date, Combination therapy: PRIMUS: Study of Imprime PGG (clinicaltrials.gov) - Jan 31, 2017
P3, N=795, Terminated, Sponsor: Biothera
Active, not recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Feb 2017; Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, the study has been terminated. No patients remain on study.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer (clinicaltrials.gov) - Jan 30, 2017
P1/2, N=17, Terminated, Sponsor: Boneca Corporation
No patients remain on study. Trial primary completion date: Dec 2013 --> Jun 2013
- || lumretuzumab (RG7116) / Roche
Enrollment change, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jan 30, 2017
P1a/1b, N=145, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2013 --> Jun 2013 N=184 --> 145
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Jan 30, 2017
P1/2, N=72, Recruiting, Sponsor: Washington University School of Medicine
N=184 --> 145 Trial primary completion date: Aug 2017 --> Aug 2018
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 30, 2017
P2, N=70, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Mar 2017 --> Dec 2017
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date, Surgery, Metastases: BOND-3: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 26, 2017
P2, N=120, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Mar 2017 --> Dec 2017 Initiation date: Mar 2015 --> Dec 2014 | Trial primary completion date: Dec 2019 --> Jun 2019
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Combination therapy, Metastases: CHANGE2: Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2017
P3, N=240, Recruiting, Sponsor: Merck KGaA
Initiation date: Mar 2015 --> Dec 2014 | Trial primary completion date: Dec 2019 --> Jun 2019 Trial primary completion date: Oct 2017 --> Aug 2018
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2/3 trial: PARECEC: Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (clinicaltrials.gov) - Jan 25, 2017
P2/3, N=154, Recruiting, Sponsor: Beijing Cancer Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jan 24, 2017
P2, N=73, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2017 --> Aug 2018 Trial primary completion date: Mar 2008 --> Oct 2007 | Active, not recruiting --> Completed
- || merestinib (LY2801653) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY2801653 in Advanced Cancer (clinicaltrials.gov) - Jan 24, 2017
P1, N=190, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Mar 2008 --> Oct 2007 | Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> May 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Monotherapy, Metastases: SAKK 41/10: Cetuximab for Elderly Patients With mCRC (clinicaltrials.gov) - Jan 24, 2017
P2, N=24, Terminated, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Nov 2017 --> May 2018 Active, not recruiting --> Terminated; FU for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of FU.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Trial primary completion date, Metastases: A Phase Ib Trial of Concurrent Cetuximab (ERBITUX (clinicaltrials.gov) - Jan 23, 2017
P1, N=18, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Terminated; FU for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of FU. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Sep 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) - Jan 21, 2017
P2, N=10, Recruiting, Sponsor: European Institute of Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Sep 2016 Trial primary completion date: Jan 2016 --> Dec 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. (Pubmed Central) - Jan 20, 2017
Trial primary completion date: Jan 2016 --> Dec 2017 Left-sided primary tumors were favored in cetuximab-based front-line targeted triplet regimen for metastatic colon cancer.
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Jan 18, 2017
P2, N=120, Recruiting, Sponsor: Pfizer
Left-sided primary tumors were favored in cetuximab-based front-line targeted triplet regimen for metastatic colon cancer. Trial primary completion date: Jun 2017 --> Mar 2018
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis (clinicaltrials.gov) - Jan 17, 2017
P2, N=40, Recruiting, Sponsor: Yonsei University
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Jan 13, 2017
P3, N=825, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: Nov 2017 --> Mar 2018
- KL 140 (cetuximab biosimilar) / Sichuan Kelun Pharma
New P1 trial, Metastases: Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 11, 2017
P1, N=18, Recruiting, Sponsor: Sichuan Kelun Pharmaceutical Co., Ltd.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, Trial primary completion date, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=30, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Nov 2017 --> Mar 2018 Trial primary completion date: Dec 2016 --> Apr 2017
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Jan 10, 2017
P2, N=80, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Dec 2016 --> Apr 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Phase classification, Trial primary completion date: Cetuximab in Treating Patients With M (clinicaltrials.gov) - Jan 10, 2017
P1, N=9, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2016 --> Apr 2017 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | Trial primary completion date: Apr 2010 --> Sep 2010
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Jan 10, 2017
P3, N=825, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | Trial primary completion date: Apr 2010 --> Sep 2010 Recruiting --> Active, not recruiting
- ||||| IMM-101 / Immodulon
New P1/2 trial, Combination therapy, Metastases: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Jan 3, 2017
P1/2, N=300, Not yet recruiting, Sponsor: Immodulon Therapeutics Ltd
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, LEAC-102 / Taiwan Bio
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 28, 2016
P1/2, N=30, Not yet recruiting, Sponsor: Taiwan Leader Biotech Corp.
Recruiting --> Active, not recruiting Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Dec 23, 2016
P3, N=154, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Initiation date: Sep 2016 --> Jan 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) - Dec 22, 2016
P2, N=10, Recruiting, Sponsor: European Institute of Oncology
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 21, 2016
P2, N=150, Recruiting, Sponsor: Boston Biomedical, Inc
Initiation date: Sep 2016 --> Jan 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- |||||||||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (clinicaltrials.gov) - Dec 21, 2016
P3, N=688, Not yet recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Biomarker, New trial, Metastases: PROSPECT-Ct: PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=47, Completed, Sponsor: Royal Marsden NHS Foundation Trust
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - Dec 16, 2016
P1/2, N=50, Enrolling by invitation, Sponsor: ArQule
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) (clinicaltrials.gov) - Dec 15, 2016
P1, N=10, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial primary completion date, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 14, 2016
P1/2, N=23, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=47 --> 23 | Trial primary completion date: Dec 2016 --> Feb 2013
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Dec 14, 2016
P3, N=466, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=47 --> 23 | Trial primary completion date: Dec 2016 --> Feb 2013 Trial primary completion date: Jan 2017 --> May 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer (clinicaltrials.gov) - Dec 13, 2016
P3, N=116, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jan 2017 --> May 2017 Trial primary completion date: Oct 2009 --> Jul 2007
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=245, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2009 --> Jul 2007 Trial primary completion date: Dec 2012 --> Apr 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=21, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2012 --> Apr 2011 Trial primary completion date: Feb 2009 --> Feb 2007
- |||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CALGB/SWOG 80405: Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 13, 2016
P3, N=2334, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Feb 2009 --> Feb 2007 Trial primary completion date: Mar 2013 --> Feb 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date: Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA (clinicaltrials.gov) - Dec 13, 2016
P1, N=30, Completed, Sponsor: Northwell Health
Trial primary completion date: Mar 2013 --> Feb 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jan 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer (clinicaltrials.gov) - Dec 9, 2016
P2, N=76, Completed, Sponsor: Institut Curie
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jan 2016 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Dec 9, 2016
P1, N=0, Withdrawn, Sponsor: University of Chicago
Recruiting --> Completed N=45 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Aug 2016
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 7, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
N=45 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Nov 2017 --> Aug 2016 Trial primary completion date: Jul 2018 --> Jan 2019
- magrolimab (ONO-7913) / Ono Pharma
Enrollment open, Combination therapy, Metastases: Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 2, 2016
P1b/2, N=112, Recruiting, Sponsor: Forty Seven, Inc.
Trial primary completion date: Jul 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
New P2 trial, Metastases: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov) - Dec 2, 2016
P2, N=50, Not yet recruiting, Sponsor: Aarti Bhatia
- | Piqray (alpelisib) / Novartis
Trial termination, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 30, 2016
P1/2, N=179, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated; early termination due to Sponsor decision (slow recruitment)
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2/3 trial, Monotherapy, Metastases: Cetuximab Monotherapy Maintenance Treatment in mCRC (clinicaltrials.gov) - Nov 30, 2016
P2/3, N=500, Not yet recruiting, Sponsor: Ruijin Hospital
- |||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Nov 25, 2016
P3, N=760, Recruiting, Sponsor: AstraZeneca
Completed --> Terminated; early termination due to Sponsor decision (slow recruitment) Suspended --> Recruiting